4.6 Review

Comorbidities in Patients with Psoriasis

期刊

AMERICAN JOURNAL OF MEDICINE
卷 122, 期 12, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2009.06.021

关键词

Cardiovascular disease; Metabolic syndrome; Psoriasis; Psoriatic arthritis comorbidities

资金

  1. Amgen
  2. Centocor, Inc
  3. Wyeth Pharmaceuticals
  4. Immune Control
  5. Celgene Corp
  6. Pharmacare
  7. Incyte
  8. Novo Nordisk
  9. Pfizer
  10. Abbott

向作者/读者索取更多资源

Psoriasis is a common chronic inflammatory disease that is associated with serious comorbidities, including psoriatic arthritis, reduced quality of life, depression, malignancy, and cardiovascular comorbidities. Patients with psoriasis have been shown to have an increased incidence of metabolic syndrome and cardiovascular disease compared with the general population. The chronic inflammatory nature of psoriasis has been suggested to be a contributing and potentially independent risk factor for the development of cardiovascular comorbidities. Understanding the interrelationship between these conditions is important for the management of psoriasis and the associated comorbidities. This review will focus on the range of comorbidities associated with psoriasis, with emphasis on cardiometabolic conditions and the aim of encouraging primary care physicians to screen psoriatic patients for cardiometabolic disorders and risk factors. (C) 2009 Elsevier Inc. All rights reserved. The American Journal of Medicine (2009) 122, 1150.e1-1150.e9

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据